Comparison of intranasal midazolam versus intravenous lorazepam for seizure termination and prevention of seizure clusters in the adult epilepsy monitoring unit.

OBJECTIVE: The objective of the study was to compare the performance of intravenous (IV) lorazepam (IVL) and intranasal midazolam (INM) for seizure termination and prevention of seizure clusters in adults admitted to the epilepsy monitoring unit (EMU) in whom seizures were captured on continuous video-electroencephalogram. METHODS: Retrospective cohort of consecutive adults (≥18 years) with epilepsy admitted to the EMU at a single tertiary academic center, who experienced epileptic seizures (confirmed electroencephalographically) and required rescue therapy. The study spanned from January 2015 until December 2016, which included one year before and one year after transitioning from IVL to INM as the standard rescue therapy at our institution. RESULTS: A total of 50 subjects received rescue therapy and were included in the analysis. In the first year, out of 216 patients with epilepsy admitted to the EMU, 27 (13%) received IVL; in the second year, 23/217 (11%) received INM. There were no differences in baseline characteristics and markers of epilepsy severity, the median duration of index seizure (1.7 min [interquartile range (IQR): 1.1-2.7] in IVL vs. 2.0 min [IQR: 1.5-2.6] in INM group, p = 0.20), or in the number of subjects requiring repeat benzodiazepine administrations (IVL 8/27 [29.6%] vs. INM 7/23 [30.4%], p = 0.95). There were no differences in the median number of recurrent seizures in 24 h (1 [IQR: 1-3] in IVL vs. 2 [IQR: 1-4] in INM, p = 0.27), occurrence of status epilepticus (IVL 4/27 [14.8%] subjects vs. INM 1/23 [4.3%] subjects, p = 0.36), incidence of seizure clusters (IVL 8/27 [29.6%] subjects vs. INM 7/23 [30.4%] subjects, p = 0.95), need for transfer to an intensive care unit (ICU), or other adverse events. SIGNIFICANCE: In our retrospective study, INM was comparable with IVL for seizure termination and prevention of seizure clusters in the adult EMU. Intranasal midazolam circumvents the need for IV access to be maintained throughout hospitalization and is an attractive alternative to IVL as a rescue therapy in this setting. Ideally, future large, prospective, randomized, and double blind studies are needed to confirm these findings.

Impact of pharmacist intervention on influenza vaccine assessment and documentation in hospitalized psychiatric patients.

PURPOSE: Results of an initiative to improve assessment and documentation of the influenza vaccination status of adult psychiatric inpatients are reported. METHODS: A prospective quality-improvement study was conducted at a large, tertiary care academic medical center with the aim of improving compliance with the Influenza Immunization (IMM-2) quality measure, which was added to the Inpatient Psychiatric Facility Quality Reporting (IPFQR) program in 2015 and requires assessment and documentation of influenza vaccination status in specified groups of psychiatric inpatients. The primary objective was to improve the IMM-2 IPFQR compliance rate to 100% during the 2015-16 influenza season from a rate of 55% during the 2014-15 influenza season through pharmacist interventions; secondary objectives included analysis of types of pharmacist interventions, rates of influenza vaccination status assessment and ordering, and rates of vaccine refusal by psychiatric disease state. RESULTS: With pharmacist interventions, the IMM-2 IPFQR compliance rate was increased to 99% during the 2015-16 influenza season. Of the 1,413 patients included in the study population, 45% (n = 646) were targeted for pharmacist intervention. Influenza vaccine was ordered for 61% of the study population (n = 867 patients), with an overall refusal rate of 74% (n = 642). Differences in refusal rates by psychiatric diagnosis were not significant. CONCLUSION: Pharmacist-conducted education of nurses and interventions to ensure completion of influenza vaccine assessments and documentation led to an improved IMM-2 IPFQR compliance rate at the study site.